Form D · Other Investment Fund
Silo Pharma, Inc.
Sarasota, FL · CIK 0001514183
Offering snapshot reported Jul 14, 2026 · SEC filing
- Reported sold
- $4M Offering amount: $4M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 14, 2026 | Initial | $4,000,015 | No comparison | 4 | SEC filing |
| Aug 2, 2024 | Initial | $2,296,880 | No comparison | 2 | SEC filing |
| Jun 11, 2024 | Initial | $2,077,409 | No comparison | 3 | SEC filing |
| Feb 22, 2021 | Initial | $4,276,000 | No comparison | 47 | SEC filing |
| May 8, 2020 | Initial | $2,399,500 | No comparison | 46 | SEC filing |
| Dec 18, 2019 | Initial | $115,000 | No comparison | 3 | SEC filing |
| Dec 18, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jul 7, 2014 | Initial | $435,000 | No comparison | 6 | SEC filing |
| Oct 11, 2013 | Amendment | $1,000,000 | No comparison | 12 | SEC filing |
| Jun 7, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Nov 22, 2011 | Initial | $6,560 | No comparison | 36 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $300K
- Finders' fees
- $0
- Form D file number
- 021-590753
In connection with the offering, H.C. Wainwright & Co., LLC received $300,002 in commissions and warrants to purchase up to 46,497 shares of common stock exercisable at $8.065 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 000000375 |
Source: Form D, filed Jul 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard A. Brand | Director, Executive |
| Wayne Linsley | Director |
| Vadim Mats | Executive |
| Kevin Munoz | Director |
| Van Parker | Director |
| Jeff Pavell | Director |
| Daniel Ryweck | Executive |
| Leonard Schiller | Director |
| Melvin Schlossberg | Director, Executive |
| Joel Stone | Director |
| Eric Weisblum | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
677 N. Washington Boulevard
Sarasota, FL, 34236
Phone: (718) 400-9031
Sarasota, FL, 34236
Phone: (718) 400-9031